Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Amdipharm UK Ltd., Capital House, 85 King William Street, London, EC4N 7BL, United Kingdom
Detrunorm 15 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. White, round, biconvex film-coated tablets. |
Each film-coated tablet contains 15 mg propiverine hydrochloride equivalent to 13.64 mg propiverine.
Excipients with known effect: Each film-coated tablet contains 100.7 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Propiverine |
Propiverine inhibits calcium influx and modulates intracellular calcium in urinary bladder smooth muscle cells causing musculotropic spasmolysis. Also, it inhibits the efferent connection of the nervus pelvicus due to anticholinergic action. |
| List of Excipients |
|---|
|
Tablet core: Lactose monohydrate Tablet film coat: Hypromellose |
They are available in PVC/PVDC/aluminium blister packs of 14, 20, 28, 30, 49, 50, 56, 60, 84, 98, 100, 112, 168, 252, 300 or 500 tablets and multipacks containing 280 (10 packs of 28) film-coated tablets.
Not all pack sizes may be marketed.
Amdipharm UK Ltd., Capital House, 85 King William Street, London, EC4N 7BL, United Kingdom
PL 20072/0243
05/08/2016
| Drug | Countries | |
|---|---|---|
| DETRUNORM | Croatia, Ireland, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
